Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blueprint And Ardelyx Join List Of Biotechs Selling Royalties To Raise Funds

Amid Market Doldrums

Executive Summary

The US firms have added to a growing number of struggling biotech companies that are selling off future royalties to help push promising drug candidates past the finish line.

You may also be interested in...



Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline

After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.

GSK Makes ADC Pipeline Comeback With Mersana Deal

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.

Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger

The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel